UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August
12, 2014
THE ALKALINE WATER COMPANY
INC.
Exact name of registrant as specified in its
charter)
Nevada |
000-55096 |
EIN 99-0367049 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
7730 E Greenway Road Ste. 203
Scottsdale, AZ
85260
(Address of principal executive offices and Zip
Code)
Registrants telephone number, including area code: (480)
656-2423
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On August 12, 2014, we entered into an agreement with H.C.
Wainwright & Co., LLC (HCW), whereby H.C. Wainwright & Co., LLC
agreed to act as our exclusive agent to facilitate the exercise of the
outstanding warrants on a reasonable best efforts basis. We agreed to pay HCW a
transaction fee equal to 10% of the aggregate gross proceeds received by us in
connection with the exercise of the warrants. In addition, we agreed to
reimburse HCW $10,000 for its legal fees and expenses, provided that no
reimbursement will be payable by us to HCW if the exercise of the warrants
results in gross proceeds to us of less than $500,000.
On August 20, 2014, we entered into a warrant amendment
agreement (the Warrant Amendment Agreement) with certain holders (the
Holders) of our outstanding common stock purchase warrants (the
Existing Warrants), whereby we agreed to reduce the exercise price of
the Existing Warrants to $0.10 per share in consideration for the immediate
exercise of the Existing Warrants by the Holders and the Holders are to be
issued new common stock purchase warrants of our company (the New
Warrants) in the form of the Existing Warrants to purchase up to a number
of shares of our common stock equal to the number of Existing Warrants exercised
by the Holders, provided that the exercise price of the New Warrants will be
$0.125 per share, subject to adjustment in the New Warrants.
On August 21, 2014, pursuant to the Warrant Amendment
Agreement, we issued an aggregate of 9,829,455 shares of our common stock upon
exercise of the Existing Warrants at an exercise price of $0.10 per share for
aggregate gross proceeds of $982,945.50. In addition, we issued New Warrants to
purchase an aggregate of 9,829,455 shares of our common stock at an exercise
price of $0.125 per share for a period of five years from the date of issuance.
An aggregate of 8,666,664 shares of our common stock issued upon exercise of the
Existing Warrants were registered under the Securities Act of 1933 pursuant to
our registration statement on Form S-1, as amended (No. 333-192599), which was
declared effective by the Securities and Exchange Commission on April 16, 2014
and in issuing the rest of shares of our common stock upon exercise of the
Existing Warrants, we relied on an exemption from the registration requirements
of the Securities Act of 1933 provided by Section 4(a)(2) of the Securities Act
of 1933 and Rule 506 promulgated thereunder. In issuing the New Warrants, we
relied on an exemption from the registration requirements of the Securities Act
of 1933 provided by Section 4(a)(2) of the Securities Act of 1933.
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Item 1.01 of this current report
on Form 8-K is responsive to this item.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
THE ALKALINE WATER COMPANY INC. |
|
|
|
|
|
/s/ Steven P.
Nickolas |
|
Steven P. Nickolas |
|
President, Chief Executive Officer and Director |
|
|
|
August 21, 2014 |
|
August 12, 2014
PERSONAL AND CONFIDENTIAL
Steven P. Nickolas
President, Chief Executive Officer and
Director
The Alkaline Water Company Inc.
7730 East Greenway Road
Suite 203
Scottsdale, AZ 85260
Dear Mr. Nickolas:
This letter will confirm the understanding and agreement (the
Agreement) between H.C. Wainwright & Co., LLC (HCW) and
The Alkaline Water Company Inc. (the Company) as follows:
|
1. |
Engagement: The Company hereby engages HCW
as its exclusive agent to facilitate the exercise (Warrant
Exercise) by the holders thereof (Holders) of outstanding
common stock purchase warrants of the Company with expiry dates of
November 21, 2014, November 7, 2018, April 16, 2019 and May 1, 2019. HCW
shall engage in discussions with the Holders regarding the terms of such
exercise and facilitate the closing of the Warrant Exercise. |
|
|
|
|
2. |
Term; Exclusivity: This exclusive
engagement will commence on the date hereof and terminate on September 30,
2014. (Term), provided that the Company can immediately terminate
this engagement if the Warrant Exercise is not completed on or before
September 1, 2014. |
|
|
|
|
3. |
Best Efforts: It is understood that HCWs
involvement in a Warrant Exercise is strictly on a reasonable best efforts
basis and that the consummation of a Warrant Exercise will be subject to,
among other things, market conditions. It is understood that HCWs
assistance in a Warrant Exercise will be subject to the satisfactory
completion of such investigation and inquiry into the affairs of the
Company as HCW deems appropriate under the circumstances (such
investigation hereinafter to be referred to as Due Diligence) and
to the receipt of all internal approvals of HCW in connection with the
Warrant Exercise. HCW shall have the right in its sole discretion to
terminate this Agreement if the outcome of the Due Diligence is not
satisfactory to HCW or if approval of its internal committees is not
obtained. |
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
1
|
4. |
Fees: As compensation for the services to
be rendered by HCW hereunder, the Company will pay HCW and amount equal to
10% of the gross proceeds received by the Company in connection with the
Warrant Exercise (Transaction Fee), which fee shall be
immediately payable upon receive by the Company of any such proceeds. HCW
may elect to retain the services of an escrow agent, at the expense and
with the written consent of the Company, to facilitate to the Warrant
Exercise and pursuant to which the Transaction Fee shall be paid directly
to HCW. The Company also agrees to reimburse HCW $10,000 for its legal
fees and expenses (the Expense Reimbursement) (provided,
however, that such expense cap in no way limits or impairs the
indemnification and contribution provisions of this Agreement), provided
that no Expense Reimbursement shall be payable by the Company to HCW if
the Warrant Exercise results in gross proceeds to the Company of less than
$500,000. The Transaction Fee and the Expense Reimbursement shall be the
only fees and expenses payable by the Company to HCW in connection with
the Warrant Exercise (provided, however, that this provision
in no way limits or impairs the indemnification and contribution
provisions of this Agreement). |
|
|
|
|
|
5. |
Indemnification: |
|
|
|
|
|
|
(a) |
To the extent permitted by law, the Company will
indemnify HCW and its affiliates, stockholders, directors, officers,
employees and controlling persons (within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act) against all losses,
claims, damages, expenses and liabilities, as the same are incurred
(including the reasonable fees and expenses of counsel), relating to or
arising out of its activities hereunder or pursuant to this engagement
letter, except to the extent that any losses, claims, damages, expenses or
liabilities (or actions in respect thereof) are found in a final judgment
(not subject to appeal) by a court of law to have resulted primarily and
directly from HCWs willful misconduct or gross negligence in performing
the services described herein. |
|
|
|
|
|
|
(b) |
Promptly after receipt by HCW of notice of any claim or
the commencement of any action or proceeding with respect to which HCW is
entitled to indemnity hereunder, HCW will notify the Company in writing of
such claim or of the commencement of such action or proceeding, and the
Company will assume the defense of such action or proceeding and will
employ counsel reasonably satisfactory to HCW and will pay the fees and
expenses of such counsel. Notwithstanding the preceding sentence, HCW will
be entitled to employ counsel separate from counsel for the Company and
from any other party in such action if counsel for HCW reasonably
determines that it would be inappropriate under the applicable rules of
professional responsibility for the same counsel to represent both the
Company and HCW. In such event, the reasonable fees
and disbursements of no more than one such separate counsel
will be paid by the Company, in addition to local counsel. The Company
will have the exclusive right to settle the claim or proceeding provided
that the Company will not settle any such claim, action or proceeding
without the prior written consent of HCW, which will not be unreasonably
withheld. |
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
2
|
(c) |
The Company agrees to notify HCW promptly of the
assertion against it or any other person of any claim or the commencement
of any action or proceeding relating to a transaction contemplated by this
engagement letter. |
|
|
|
|
(d) |
If for any reason the foregoing indemnity is unavailable
to HCW or insufficient to hold HCW harmless, then the Company shall
contribute to the amount paid or payable by HCW as a result of such
losses, claims, damages or liabilities in such proportion as is
appropriate to reflect not only the relative benefits received by the
Company on the one hand and HCW on the other, but also the relative fault
of the Company on the one hand and HCW on the other that resulted in such
losses, claims, damages or liabilities, as well as any relevant equitable
considerations. The amounts paid or payable by a party in respect of
losses, claims, damages and liabilities referred to above shall be deemed
to include any legal or other fees and expenses incurred in defending any
litigation, proceeding or other action or claim. Notwithstanding the
provisions hereof, HCWs share of the liability hereunder shall not be in
excess of the amount of fees actually received, or to be received, by HCW
under this engagement letter (excluding any amounts received as
reimbursement of expenses incurred by HCW). |
|
|
|
|
(e) |
These indemnification provisions shall remain in full
force and effect whether or not the transaction contemplated by this
engagement letter is completed and shall survive the termination of this
engagement letter, and shall be in addition to any liability that the
Company might otherwise have to any indemnified party under this
engagement letter or otherwise. |
|
6. |
Governing Laws: This letter agreement will
be governed by and construed in accordance with the laws of the State of
New York applicable to agreements made and to be fully performed therein.
The Company irrevocably submits to the jurisdiction of any court of the
State of New York located in the City and County of New York or in the
United States District Court for the Southern District of New York for the
purpose of any suit, action or other proceeding arising out of this letter
agreement or our engagement hereunder. |
|
|
|
|
|
Each of the Company and HCW hereby waives any right it
may have to a trial by jury in respect of any claim brought by or on
behalf of either party based upon, arising out of or in connection with this letter
agreement, our engagement hereunder or the transaction contemplated
hereby. |
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
3
|
|
All fees and expenses payable hereunder will be payable
in U.S. dollars in cash. The Company hereby irrevocably consents to the
service of process in any proceeding by the mailing of copies of such
process to the Company at its address set forth above. |
|
|
|
|
7. |
No Brokers: The Company represents and
warrants to HCW that there are no brokers, representatives or other
persons which have an interest in compensation due to HCW from any
transaction contemplated herein or which would otherwise be due any fee,
commission or remuneration upon consummation of any Warrant
Exercise. |
|
|
|
|
8. |
Authorization: The Company and HCW
represent and warrant that each has all requisite power and authority to
enter into and carry out the terms and provisions of this Agreement and
the execution, delivery and performance of this Agreement does not breach
or conflict with any agreement, document or instrument to which it is a
party or bound. |
|
|
|
|
9. |
Independent Contractor: The Company
acknowledges that in performing its services, HCW is acting as an
independent contractor, and not as a fiduciary, agent or otherwise, of the
Company or any other person. The Company acknowledges that in performing
its services hereunder, HCW shall act solely pursuant to a contractual
relationship on an arms length basis (including in connection with
determining the terms of any Warrant Exercise). Any review by HCW of the
Company, the transaction contemplated hereby or other matters relating to
such transactions has been and shall be performed solely for the benefit
of HCW and shall not be on behalf of the Company. The Company agrees that
is shall not claim that HCW owes a fiduciary duty to the Company in
connection with such transaction or the process leading thereto. No one
other than the Company is authorized to rely upon engagement of HCW
hereunder or any statements, advice, opinions or conduct by HCW. The
Company further acknowledges that HCW may perform certain of the services
described herein through one or more of its affiliates and any such
affiliates shall be entitled to the benefit of this Agreement. This
Paragraph 9 shall survive the termination or expiration of this
Agreement. |
|
|
|
|
10. |
Conflicts: The Company acknowledges that
HCW and its affiliates may have and may continue to have investment
banking and other relationships with parties other than the Company
pursuant to which HCW may acquire information of interest to the Company.
HCW shall have no obligation to disclose such information to the Company
or to use such information in connection with any contemplated
transaction. |
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
4
|
11. |
Anti-Money Laundering: To help the United
States government fight the funding of terrorism and money laundering, the
federal laws of the United States requires all financial institutions to
obtain, verify and record information that identifies each person with
whom they do business. This means we must ask you for certain identifying
information, including a government-issued identification number (e.g., a
U.S. taxpayer identification number) and such other information or
documents that we consider appropriate to verify your identity, such as
certified articles of incorporation, a government-issued business license,
a partnership agreement or a trust instrument. |
|
|
|
|
12. |
Miscellaneous: This Agreement constitutes
the entire understanding and agreement between the Company and HCW with
respect to the subject matter hereof and supersedes all prior
understanding or agreements between the parties with respect thereto,
whether oral or written, express or implied; provided,
however, nothing hereunder shall supersede or modify
that certain engagement agreement, dated March 12, 3014, which shall
remain in full force and effect. Any amendments or modifications must
be executed in writing by both parties. It is understood and agreed that
HCWs services hereunder will not include providing any tax, accounting,
legal or regulatory advice or developing any tax strategies for the
Company. This Agreement and all rights, liabilities and obligations
hereunder shall be binding upon and inure to the benefit of each partys
successors but may not be assigned without prior written approval of the
other party. This Agreement may be executed in any number of counterparts,
each of which shall be deemed to be an original, but such counterparts
shall, together, constitute only one instrument. The descriptive headings
of the Paragraphs of this Agreement are inserted for convenience only, do
not constitute a part of this Agreement and shall not affect in anyway the
meaning or interpretation of this Agreement. |
*********************
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
5
If all the foregoing is acceptable to you, please so indicate by signing in the
space provided below and returning a signed copy of this letter to us for our
records.
HCW is delighted to accept this engagement and looks forward to working with
you. Please confirm that the foregoing correctly set forth our agreement by
signing the enclosed duplicate of this letter in the space provided and
returning it, whereupon this letter shall constitute a binding agreement as of
the date first above written.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
|
By: |
/s/ Mark W. Viklund |
|
|
Name: Mark W. Viklund |
|
|
Title: CEO |
ACCEPTED AND AGREED TO
AS OF THE ABOVE DATE:
THE ALKALINE WATER COMPANY INC.
BY: |
/s/ Steven P. Nickolas |
|
|
Name: Steven P. Nickolas |
|
|
Title: President/CEO |
|
430 Park Avenue | New York, New York 10022 | 212.356.0500 |
www.hcwco.com
Member: FINRA/SIPC
6
WARRANT AMENDMENT AGREEMENT
This
Warrant Amendment Agreement (the Agreement), dated as of August ___,
2014, is by and among The Alkaline Water Company Inc., a Nevada corporation (the
Company) and the undersigned holder of common stock purchase warrants
(Existing Warrants) of the Company (the Holder).
WHEREAS, the Holder currently holds the Existing Warrants as set forth on the
Holders signature page attached hereto; and
WHEREAS, the parties wish to amend certain terms of the Existing Warrants in
consideration for the immediate exercise of the Existing Warrants by the Holder
and, pursuant to Section 4(a)(2) of the Securities Act, the issuance of new
common stock purchase warrants of the Company (New Warrants) to the
Holder.
NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
and for good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Holders and the Company agree as follows:
ARTICLE I
DEFINITIONS
Section
1.1 Definitions. Capitalized
terms not defined in this Agreement shall have the meanings ascribed to such
terms in the Existing Warrants.
ARTICLE II
EXERCISE OF WARRANTS,
AMENDMENTS AND OTHER AGREEMENTS
Section
2.1 Exercise of Existing
Warrants. Holder hereby agrees to exercise all of such Holders Existing
Warrants (except to the extent indicated on the signature page hereto) at an
exercise price of $0.10 per share, otherwise pursuant to the terms of the
Existing Warrants. At the Closing (as defined below), the Holder shall deliver
the aggregate cash exercise price for such Existing Warrants to the bank account
designated in writing by the Company. This Agreement shall act as a duly
executed Notice of Exercise and no additional notice shall be required by the
Holder for the exercise of the Existing Warrants. At the Closing, the Company
shall deliver to the Holder the shares underlying the Existing Warrants (the
Existing Warrant Shares) via DRS as set forth on the Holders signature page
hereto. Such Existing Warrant Shares shall be subject to an effective
registration statement registering the sale or resale, as the case may be, of
such Existing Warrant Shares.
Section
2.2 Issuance of New Warrants.
The Holder shall be issued New Warrants (hereinafter also referred to as
Warrants) in the form of the Existing Warrants to purchase up to a
number of shares of Common Stock equal to the number of Existing Warrants
exercised by the Holder hereunder provided that the exercise price
thereunder shall be $0.125 , subject to adjustment therein. The shares of Common
Stock underlying such Warrants shall be referred to herein as the New Warrant Shares. The date of the closing of the exercise of the Existing
Warrants and other transactions contemplated hereunder shall be referred to as
the Closing. The Company and the Holder hereby agree that the term
Warrants and Warrant Shares as defined under that certain Securities
Purchase Agreement, dated November 4, 2013 shall hereafter be deemed to include
the New Warrants and New Warrant Shares issued hereunder and the Company shall
have the same obligations to the Holder, and the Holder the same rights, with
respect to the New Warrants and New Warrant Shares as a holder of the Warrants
and Warrant Shares under such Securities Purchase Agreement (whether or not the
Holder was originally a party to such agreement). Notwithstanding anything in
this Agreement to the contrary, the Company shall not be required to file a
registration statement registering the New Warrants or New Warrant Shares for
sale or resale under the Securities Act. The New Warrants and underlying New
Warrant Shares may only be disposed of in compliance with state and federal
securities laws.
1
Section
2.3 Filing of Form 8-K and
Prospectus Supplement. Within 1 Trading Day of the date hereof, the Company
shall issue a Current Report on Form 8-K (and any prospectus supplement relating
to the Existing Warrants if required by law), reasonably acceptable to each
Holder.
Section
2.4 Conditions to Holders
Obligations. The obligations of the Holder hereunder in connection with the
Closing are subject to the following conditions being met:
(a)
the accuracy in all material respects on the date of the Closing of the
representations and warranties of the Company contained herein;
(b)
a registration statement registering the all of the Existing Warrant Shares for
sale or resale, as the case may be, shall be effective as of the Closing Date
and the Company shall have filed a prospectus supplement to such registration
statement permitting the sale or resale, as the case may be, of the Existing
Warrant Shares;
(c)
all obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing shall have been performed;
(d)
the delivery of a Secretarys Certificate, attaching the Board of Directors
resolutions approving the transactions contemplated hereby;
(e)
there shall have been no Material Adverse Effect with respect to the Company
since the date hereof; and
(f)
from the date hereof to the Closing, trading in the Common Stock shall not have
been suspended by the Commission (except for any suspension of trading of
limited duration agreed to by the Company, which suspension shall be terminated
prior to the Closing), and, at any time prior to the Closing, trading in
securities generally as reported by Bloomberg Financial Markets shall not have
been suspended or limited, or minimum prices shall not have been established
on securities whose trades are reported by such service, or on any Trading
Market, nor shall a banking moratorium have been declared either by the United
States or New York State authorities nor shall there have occurred any material
outbreak or escalation of hostilities or other national or international
calamity of such magnitude in its effect on, or any material adverse change in,
any financial market which, in each case, in the reasonable judgment of each
Holder, makes it impracticable or inadvisable to consummate the transactions
hereunder.
2
ARTICLE III
REPRESENTATIONS AND WARRANTIES
Section
3.1 Representations and Warranties
of the Company. The Company hereby make the representations and warranties
set forth below to the Holder that as of the date of its execution of this
Agreement:
(a)
Authorization; Enforcement. The Company has the requisite corporate power
and authority to enter into and to consummate the transactions contemplated by
this Agreement and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of this Agreement by the Company and the
consummation by it of the transactions contemplated hereby have been duly
authorized by all necessary action on the part of such Company and no further
action is required by such Company, its board of directors or its stockholders
in connection therewith. This Agreement has been duly executed by the Company
and, when delivered in accordance with the terms hereof will constitute the
valid and binding obligation of the Company enforceable against the Company in
accordance with its terms except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting enforcement of creditors rights generally,
(ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law.
(b)
No Conflicts. The execution, delivery and performance of this Agreement
by the Company and the consummation by the Company of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any
provision of the Companys certificate or articles of incorporation, bylaws or
other organizational or charter documents, or (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a
default) under, result in the creation of any lien upon any of the properties or
assets of the Company, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of,
any material agreement, credit facility, debt or other material instrument
(evidencing Company debt or otherwise) or other material understanding to which
the Company is a party or by which any property or asset of the Company is bound
or affected, or (iii) conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other restriction of any
court or governmental authority to which the Company is subject (including
federal and state securities laws and regulations), or by which any property or
asset of the Company is bound or affected.
3
(c)
Organization; Capitalization. The Company is a duly organized and validly
existing corporation in good standing under the laws of the State of Nevada. The
Warrants and Warrant Shares, when issued in accordance with the terms of this
Agreement and the Warrants, will be duly authorized, validly issued, fully paid
and nonassessable.
(d)
Issuance of the New Warrants; Registration of Existing Warrant Shares.
The New Warrants are duly authorized and, when issued and paid for in accordance
with this Agreement, will be duly and validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The New
Warrant Shares underlying the New Warrants, when issued in accordance with the
terms of the Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Company has reserved
from its duly authorized capital stock the maximum number of shares of Common
Stock issuable pursuant to this Agreement and the Existing Warrants. The Company
has prepared and filed a registration statement(s) in conformity with the
requirements of the Securities Act, which are currently effective and available
for use by the Company for the sale, or by the Holder for resale, as the case
may be, of the Existing Warrant Shares. No stop order preventing or suspending
the effectiveness of such registration statement or suspending or preventing the
use of the prospectuses thereunder has been issued by the Commission and no
proceedings for that purpose have been instituted or, to the knowledge of the
Company, are threatened by the Commission. At the time such registration
statements and any amendments thereto became effective, at the date of this
Agreement and at the Closing Date, such registration statement and any
amendments thereto conformed and will conform in all material respects to the
requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading; and
the prospectus and any amendments or supplements thereto, at time such
prospectus or any amendment or supplement thereto was issued and at the Closing
Date, conformed and will conform in all material respects to the requirements of
the Securities Act and did not and will not contain an untrue statement of a
material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made,
not misleading.
Section
3.2 Representations and Warranties
of the Holder. The Holder hereby makes the representations and warranties
set forth below to the Company that as of the date of its execution of this
Agreement:
(a)
Due Authorization. The Holder represents and warrants that (i) the
execution and delivery of this Agreement by it and the consummation by it of the
transactions contemplated hereby have been duly authorized by all necessary
action on its behalf and (ii) this Agreement has been duly executed and
delivered by the Holder and constitutes the valid and binding
obligation of the Holder, enforceable against it in accordance with its terms.
4
(b)
No Conflicts. The execution, delivery and performance of this Agreement
by the Holder and the consummation by the Holder of the transactions
contemplated hereby do not and will not: (i) conflict with or violate any
provision of the Holders organizational or charter documents, or (ii) conflict
with or result in a violation of any agreement, law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental
authority which would interfere with the ability of the Holder to perform its
obligations under this Agreement.
(c)
Own Account. Such Purchaser understands that the New Warrants and the New
Warrant Shares, when issued, will be restricted securities and have not been
registered under the Securities Act or any applicable state securities law and
is acquiring the New Warrants and New Warrant Shares as principal for its own
account and not with a view to or for distributing or reselling such New
Warrants and New Warrant Shares or any part thereof in violation of the
Securities Act or any applicable state securities law, has no present intention
of distributing any of such New Warrants and New Warrant Shares in violation of
the Securities Act or any applicable state securities law and has no direct or
indirect arrangement or understandings with any other persons to distribute or
regarding the distribution of such New Warrants or New Warrant Shares in
violation of the Securities Act or any applicable state securities law (this
representation and warranty not limiting such Purchasers right to sell the New
Warrants and New Warrant Shares pursuant to a registration statement or
otherwise in compliance with applicable federal and state securities laws). Such
Purchaser is acquiring the New Warrants and New Warrant Shares hereunder in the
ordinary course of its business.
(d)
Purchaser Status. At the time such Purchaser was offered the New
Warrants, it was, and as of the date hereof it is, and on each date on which it
exercises any New Warrants, it will be an accredited investor as defined in
Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.
(e)
General Solicitation. Such Purchaser is not entering into this Agreement
as a result of any advertisement, article, notice or other communication
regarding the transactions contemplated hereunder published in any newspaper,
magazine or similar media or broadcast over television or radio or presented at
any seminar or any other general solicitation or general advertisement.
ARTICLE IV
MISCELLANEOUS
Section
4.1 Notices. Any and all
notices or other communications or deliveries required or permitted to be
provided hereunder shall be made in accordance with the provisions of the
Purchase Agreement.
5
Section
4.2 Survival. All warranties
and representations (as of the date such warranties and representations were
made) made herein or in any certificate or other instrument delivered by it or
on its behalf under this Agreement shall be considered to have been relied upon
by the parties hereto and shall survive the exercise of the Existing Warrants
and the issuance of the New Warrants. This Agreement shall inure to the benefit
of and be binding upon the successors and permitted assigns of each of the
parties; provided however that no party may assign this Agreement or the
obligations and rights of such party hereunder without the prior written consent
of the other parties hereto.
Section
4.3 Execution. This Agreement
may be executed in two or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when
counterparts have been signed by each party and delivered to the other party, it
being understood that both parties need not sign the same counterpart. In the
event that any signature is delivered by facsimile transmission, such signature
shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such
facsimile signature page were an original thereof.
Section
4.4 Severability. If any
provision of this Agreement is held to be invalid or unenforceable in any
respect, the validity and enforceability of the remaining terms and provisions
of this Agreement shall not in any way be affected or impaired thereby and the
parties will attempt to agree upon a valid and enforceable provision that is a
reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.
Section
4.5 Governing Law. All
questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be determined pursuant to the Governing Law provision of
the Warrant.
Section
4.6 Entire Agreement. The
Agreement, together with the exhibits and schedules thereto, contain the entire
understanding of the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.
Section
4.7 Construction. The headings
herein are for convenience only, do not constitute a part of this Agreement and
shall not be deemed to limit or affect any of the provisions hereof. The
language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will
be applied against any party.
Section
4.8 Termination. This Agreement
may be terminated by any Holder, as to such Holders obligations hereunder, by
written notice to the other parties, if the Closing has not been consummated on
or before August 22, 2014.
6
Section
4.10 Fees and Expenses. Except as expressly
set forth herein, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and
performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection
with the delivery of any Warrants or Warrant Shares.
***********************
7
IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed by their respective authorized signatories as of the date first
indicated above.
THE ALKALINE WATER COMPANY
INC.
By:
__________________________________________
Name:
Title:
8
[HOLDER SIGNATURE PAGES TO WTER
WARRANT AMENDMENT AGREEMENT]
IN WITNESS WHEREOF, the undersigned have caused
this Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.
Name of Holder:
__________________________________________________________________________________________________
Signature
of Authorized Signatory of Holder:
___________________________________________________________________________
Name
of Authorized Signatory:
______________________________________________________________________________________
Title
of Authorized Signatory:
_______________________________________________________________________________________
Email
Address of Holder:
___________________________________________________________________________________________
Registration Name and Address for Existing Warrant Shares and
New Warrants:
______________________________________________________________________________________________________________
______________________________________________________________________________________________________________
______________________________________________________________________________________________________________
Tax ID#: ______________
Address for Delivery of New Warrants for Holder (if not same as
above):
Number of Existing Warrants: ______________
[Excluded
Existing Warrants:________________]
Aggregate Exercise Price (@ $0.10): $______________
New Warrants (100% of Existing Warrants):
_________________
9
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS
SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
SECURITIES ACT), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO
THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON
EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.
COMMON STOCK PURCHASE WARRANT
THE ALKALINE WATER COMPANY INC.
Warrant Shares: |
Initial Exercise Date: August 21, 2014
|
THIS
COMMON STOCK PURCHASE WARRANT (the Warrant) certifies that, for value
received, _____________or its assigns (the Holder) is entitled, upon the terms
and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the Initial Exercise
Date) and on or prior to the close of business on the five (5) year
anniversary of the Initial Exercise Date (the Termination Date) but not
thereafter, to subscribe for and purchase from The Alkaline Water Company Inc.,
a Nevada corporation (the Company), up to ______shares (as subject to
adjustment hereunder, the Warrant Shares) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the
Exercise Price, as defined in Section 2(b).
Section
1. Definitions. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement (the Purchase
Agreement), dated November 4, 2013, among the Company and the purchasers
signatory thereto.
Section 2. Exercise.
a) Exercise of Warrant.
Exercise of the purchase rights represented by this Warrant may be made, in
whole or in part, at any time or times on or after the Initial Exercise Date and
on or before the Termination Date by delivery to the Company (or such other
office or agency of the Company as it may designate by notice in writing to the
registered Holder at the address of the Holder appearing on the books of the
Company) of a duly executed facsimile copy of the Notice of Exercise in the form
annexed hereto and within three (3) Trading Days of the date said Notice of
Exercise is delivered to the Company, the Company
shall have received payment of the aggregate Exercise Price of the shares
thereby purchased by wire transfer or cashiers check drawn on a United States
bank or, if available, pursuant to the cashless exercise procedure specified in
Section 2(c) below. No ink-original Notice of Exercise shall be required, nor
shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise form be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares
available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within
three (3) Trading Days of the date the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares
purchased. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of
receipt of such notice. The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time
may be less than the amount stated on the face hereof.
1
b) Exercise Price. The
exercise price per share of the Common Stock under this Warrant shall be
$0.125, subject to adjustment hereunder (the Exercise Price).
c) Cashless Exercise. If at any
time after February 21, 2015, there is no effective registration statement
registering, or no current prospectus available for, the resale of the Warrant
Shares by the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a cashless exercise in which the Holder shall
be entitled to receive a number of Warrant Shares equal to the quotient obtained
by dividing [(A-B) (X)] by (A), where:
|
(A) = |
the VWAP on the Trading Day immediately preceding the
date on which Holder elects to exercise this Warrant by means of a
cashless exercise, as set forth in the applicable Notice of Exercise;
|
|
|
|
|
(B) = |
the Exercise Price of this Warrant, as adjusted
hereunder; and |
|
|
|
|
(X) = |
the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if
such exercise were by means of a cash exercise rather than a cashless
exercise. |
d) Mechanics of Exercise.
i. Delivery of Warrant Shares Upon
Exercise. Warrant Shares purchased hereunder shall be transmitted by the
Transfer Agent to the Holder by the date that is two (2)
Trading Days after the delivery to the Company of the Notice of Exercise (such
date, the "Warrant Share Delivery Date"). On or after the earlier
of the date that (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
or (B) February 21, 2015, the Company shall deliver any Warrant Shares via DRS
as set forth on the Notice of Exercise. The Warrant Shares shall be deemed to
have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Warrant has been exercised, with payment to the
Company of the Exercise Price (or by cashless exercise, if permitted) and all
taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of
Exercise by the Warrant Share Delivery Date, the Company shall pay to the
Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of
Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after such
liquidated damages begin to accrue) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds
such exercise.
2
ii. Delivery of New Warrants Upon
Exercise. If this Warrant shall have been exercised in part, the Company
shall, at the request of a Holder and upon surrender of this Warrant
certificate, at the time of delivery of the Warrant Shares, deliver to the
Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.
iii.
Rescission Rights. If the Company fails to cause the Transfer Agent to
transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the
Warrant Share Delivery Date, then the Holder will have the right to rescind such
exercise.
iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares
Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the
Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holders brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale
by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a Buy-In), then the Company shall (A) pay in cash to the Holder the amount, if any,
by which (x) the Holders total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y) the amount
obtained by multiplying (1) the number of Warrant Shares that the Company was
required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or
deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery
obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The
Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company,
evidence of the amount of such loss. Nothing herein shall limit a Holders right
to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Companys failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.
3
v. No Fractional Shares or
Scrip. No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant. As to any fraction of a share which
the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the Exercise
Price or round up to the next whole share.
vi. Charges, Taxes and
Expenses. Issuance of Warrant Shares shall be made without charge to the
Holder for any issue or transfer tax or other incidental expense in respect of
the issuance of Warrant Shares, all of which taxes and expenses shall be paid by
the Company, and such Warrant Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name
other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the
Holder and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise.
4
vii. Closing of Books. The
Company will not close its stockholder books or records in any manner which
prevents the timely exercise of this Warrant, pursuant to the terms hereof.
e) Holders Exercise
Limitations. The Company shall not effect any exercise of this Warrant, and
a Holder shall not have the right to exercise any portion of this Warrant,
pursuant to Section 2 or otherwise, to the extent that after giving effect to
such issuance after exercise as set forth on the applicable Notice of Exercise,
the Holder (together with the Holders Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holders Affiliates), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the
number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercised portion of this Warrant beneficially owned by the Holder
or any of its Affiliates and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without
limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the
rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation
is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To
the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holders determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a determination as to
any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Companys most recent
periodic or annual report filed with the Commission, as the case may be, (B) a
more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding. Upon the written or oral
request of a Holder, the Company shall within two Trading Days confirm orally
and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates since the
date as of which such number of outstanding shares of Common Stock was reported.
The Beneficial Ownership Limitation shall be 4.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock issuable upon exercise of this Warrant. The
Holder, upon not less than 61 days prior notice to the Company, may increase or
decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of
the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to
apply. Any such increase or decrease will not be effective until the
61st day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to
correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.
5
Section 3.
Certain Adjustments.
a) Stock Dividends and Splits.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its
Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any
shares of Common Stock issued by the Company upon exercise of this Warrant),
(ii) subdivides outstanding shares of Common Stock into a larger number of
shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of
the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock
(excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision, combination or re-classification.
6
b) Subsequent Equity Sales. If
the Company or any Subsidiary thereof, as applicable, at any time while this
Warrant is outstanding, shall sell or grant any option to purchase, or sell or
grant any right to reprice, or otherwise dispose of or issue (or announce any
offer, sale, grant or any option to purchase or other disposition) any Common
Stock or Common Stock Equivalents, at an effective price per share less than the
Exercise Price then in effect (such lower price, the Base Share Price and such
issuances collectively, a Dilutive Issuance) (it being understood and
agreed that if the holder of the Common Stock or Common Stock Equivalents so
issued shall at any time, whether by operation of purchase price adjustments,
reset provisions, floating conversion, exercise or exchange prices or otherwise,
or due to warrants, options or rights per share which are issued in connection
with such issuance, be entitled to receive shares of Common Stock at an
effective price per share that is less than the Exercise Price, such issuance
shall be deemed to have occurred for less than the Exercise Price on such date
of the Dilutive Issuance at such effective price), then simultaneously with the
consummation of each Dilutive Issuance the Exercise Price shall be reduced and
only reduced to equal the Base Share Price. Such adjustment shall be made
whenever such Common Stock or Common Stock Equivalents are issued.
Notwithstanding the foregoing, no adjustments shall be made, paid or issued
under this Section 3(b) in respect of an Exempt Issuance (provided that for the
purpose of this Section 3(b), the phrase the date of this Agreement contained
in the definition of Exempt Issuance in the Purchase Agreement shall be read
to be August 21, 2014). The Company shall notify the Holder, in writing, no
later than the Trading Day following the issuance or deemed issuance of any
Common Stock or Common Stock Equivalents subject to this Section 3(b),
indicating therein the applicable issuance price, or applicable reset price,
exchange price, conversion price and other pricing terms (such notice, the
Dilutive Issuance Notice). For purposes of clarification, whether or
not the Company provides a Dilutive Issuance Notice pursuant to this Section
3(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to
receive a number of Warrant Shares based upon the Base Share Price regardless of
whether the Holder accurately refers to the Base Share Price in the Notice of
Exercise. If the Company enters into a Variable Rate Transaction, despite the
prohibition thereon in the Purchase Agreement, the Company shall be deemed to
have issued Common Stock or Common Stock Equivalents at the lowest possible
conversion or exercise price at which such securities may be converted or
exercised
c) Subsequent Rights Offerings.
In addition to any adjustments pursuant to Section 3(a) above, if at any time
the Company grants, issues or sells any Common Stock Equivalents or rights to
purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the Purchase Rights),
then the Holder will be entitled to acquire, upon the terms applicable to such
Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date on which a record is taken for the
grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of
shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (provided, however, to the extent that the Holders right to
participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Purchase Right to such extent (or beneficial ownership of
such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder
until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).
7
d) Pro Rata Distributions.
During such time as this Warrant is outstanding, if the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or
other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a "Distribution"), at any time after the issuance
of this Warrant, then, in each such case, the Holder shall be entitled to
participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any
limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the
participation in such Distribution (provided, however, to the
extent that the Holder's right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of
such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).
8
e) Fundamental Transaction. If,
at any time while this Warrant is outstanding, (i) the Company, directly or
indirectly, in one or more related transactions effects any merger or
consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has
been accepted by the holders of 50% or more of the outstanding Common Stock,
(iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of
arrangement) with another Person or group of Persons whereby such other Person
or group acquires more than 50% of the outstanding shares of Common Stock (not
including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or
party to, such stock or share purchase agreement or other business combination)
(each a Fundamental Transaction), then, upon any subsequent exercise of
this Warrant, the Holder shall have the right to receive, for each Warrant Share
that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the
number of shares of Common Stock of the successor or acquiring corporation or of
the Company, if it is the surviving corporation, and any additional
consideration (the Alternate Consideration) receivable as a result of
such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of
this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company
shall apportion the Exercise Price among the Alternate Consideration in a
reasonable manner reflecting the relative value of any different components of
the Alternate Consideration. If holders of Common Stock are given any choice as
to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental
Transaction. Notwithstanding anything to the contrary, the Company or any
Successor Entity (as defined below) shall, at the Holders option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the
Fundamental Transaction, purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value of the remaining
unexercised portion of this Warrant on the date of the consummation of such
Fundamental Transaction. Black Scholes Value means the value of
this Warrant based on the Black and Scholes Option Pricing Model obtained from
the OV function on Bloomberg, L.P. (Bloomberg) determined as of the
day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A) a risk-free interest rate corresponding to the U.S.
Treasury rate for a period equal to the time between the date of the public
announcement of the applicable Fundamental Transaction and the Termination Date,
(B) an expected volatility equal to the greater of 100% and the 100 day
volatility obtained from the HVT function on Bloomberg as of the Trading Day
immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall
be the sum of the price per share being offered in cash, if any, plus the value
of any non-cash consideration, if any, being offered in such Fundamental
Transaction and (D) a remaining option time equal to the time between the date
of the public announcement of the applicable Fundamental Transaction and the
Termination Date. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the Successor Entity) to
assume in writing all of the obligations of the Company under this Warrant and
the other Transaction Documents in accordance with the provisions of this
Section 3(e) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this Warrant a security of the
Successor Entity evidenced by a written instrument substantially similar in form
and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which
applies the exercise price hereunder to such shares of capital stock (but taking
into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be
substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant and the other Transaction Documents
referring to the Company shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the
Company herein.
9
f) Calculations. All
calculations under this Section 3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding
treasury shares, if any) issued and outstanding.
g) Notice to Holder.
i. Adjustment to Exercise Price. Whenever
the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly mail to the Holder a notice setting forth the Exercise
Price after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts requiring such
adjustment..
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare
a dividend (or any other distribution in whatever form) on the Common Stock, (B)
the Company shall declare a special nonrecurring cash dividend on or a
redemption of the Common Stock, (C) the Company shall authorize the granting to
all holders of the Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of
any stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or
merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the
Company shall cause to be mailed to the Holder at its last address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior
to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the
failure to mail such notice or any defect therein or in the mailing thereof
shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or
contains, material, non-public information regarding the Company or any of the
Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as
may otherwise be expressly set forth herein.
10
Section 4.
Transfer of Warrant.
a) Transferability. Subject to
compliance with any applicable securities laws and the conditions set forth in
Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase
Agreement, this Warrant and all rights hereunder are transferable, in whole or
in part, upon surrender of this Warrant at the principal office of the Company
or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of
the assignee or assignees, as applicable, and in the denomination or
denominations specified in such instrument of assignment, and shall issue to the
assignor a new Warrant evidencing the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Notwithstanding anything herein to
the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company unless the Holder has assigned this Warrant in full, in
which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date the Holder delivers an assignment form to the Company
assigning this Warrant full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares
without having a new Warrant issued.
11
b) New Warrants. This Warrant
may be divided or combined with other Warrants upon presentation hereof at the
aforesaid office of the Company, together with a written notice specifying the
names and denominations in which new Warrants are to be issued, signed by the
Holder or its agent or attorney. Subject to compliance with Section 4(a), as to
any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant
or Warrants to be divided or combined in accordance with such notice. All
Warrants issued on transfers or exchanges shall be dated the Initial Exercise
Date and shall be identical with this Warrant except as to the number of Warrant
Shares issuable pursuant thereto.
c) Warrant Register. The
Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the Warrant Register), in the name of the
record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose
of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.
d) Transfer Restrictions. If,
at the time of the surrender of this Warrant in connection with any transfer of
this Warrant, the transfer of this Warrant shall not be either (i) registered
pursuant to an effective registration statement under the Securities Act and
under applicable state securities or blue sky laws or (ii) eligible for resale
without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of
allowing such transfer, that the Holder or transferee of this Warrant, as the
case may be, comply with the provisions of Section 5.7 of the Purchase
Agreement.
e) Representation by the
Holder. The Holder, by the acceptance hereof, represents and warrants that
it is acquiring this Warrant and, upon any exercise hereof, will acquire the
Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof
in violation of the Securities Act or any applicable state securities law,
except pursuant to sales registered or exempted under the Securities Act.
Section 5.
Miscellaneous.
a) No Rights as Stockholder Until
Exercise. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise
hereof as set forth in Section 2(d)(i), except as expressly set forth in Section
3.
b) Loss, Theft, Destruction or
Mutilation of Warrant. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or
any stock certificate relating to the Warrant Shares, and in case of loss, theft
or destruction, of indemnity or security reasonably satisfactory to it (which,
in the case of the Warrant, shall not include the posting of any bond), and upon
surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock
certificate.
12
c) Saturdays, Sundays, Holidays,
etc. If the last or appointed day for the taking of any action or the
expiration of any right required or granted herein shall not be a Business Day,
then, such action may be taken or such right may be exercised on the next
succeeding Business Day.
d) Authorized Shares.
The
Company covenants that, during the period the Warrant is outstanding, it will
reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are
charged with the duty of issuing the necessary Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be
issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).
Except
and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will
(i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value,
(ii) take all such action as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Warrant
Shares upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or
consents from any public regulatory body having jurisdiction thereof, as may be,
necessary to enable the Company to perform its obligations under this Warrant.
13
Before
taking any action which would result in an adjustment in the number of Warrant
Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.
e) Jurisdiction. All questions concerning the
construction, validity, enforcement and interpretation of this Warrant shall be
determined in accordance with the provisions of the Purchase Agreement.
f) Restrictions. The Holder acknowledges that the Warrant Shares acquired
upon the exercise of this Warrant, if not registered and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state
and federal securities laws.
g) Nonwaiver and Expenses. No
course of dealing or any delay or failure to exercise any right hereunder on the
part of Holder shall operate as a waiver of such right or otherwise prejudice
the Holders rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and
knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys fees, including those of appellate
proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.
h) Notices. Any notice, request
or other document required or permitted to be given or delivered to the Holder
by the Company shall be delivered in accordance with the notice provisions of
the Purchase Agreement.
i) Limitation of Liability. No
provision hereof, in the absence of any affirmative action by the Holder to
exercise this Warrant to purchase Warrant Shares, and no enumeration herein of
the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the
Company, whether such liability is asserted by the Company or by creditors of
the Company.
j) Remedies. The Holder, in
addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees to waive and not to assert the
defense in any action for specific performance that a remedy at law would be
adequate.
14
k)
Successors and Assigns. Subject to applicable securities laws, this
Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the
Company and the successors and permitted assigns of Holder. The provisions of
this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant
Shares.
l) Amendment. This Warrant may
be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.
m) Severability. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of
this Warrant.
n) Headings. The headings used
in this Warrant are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Warrant.
********************
(Signature Page Follows)
15
IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date
first above indicated.
THE ALKALINE WATER COMPANY INC.
By:
_____________________________________________________________
Name:
Title:
16
NOTICE OF EXERCISE
TO: THE ALKINE WATER
COMPANY INC.
(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company
pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.
(2)
Payment shall take the form of (check applicable box):
[ ] in lawful money of the United
States; or
[ ] [if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Warrant with respect to the
maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).
(3)
Please issue said Warrant Shares in the name of the undersigned or in such other
name as is specified below:
Registration Name and Address for Warrant Shares:
_____________________________________
_____________________________________
_____________________________________
_____________________________________
Tax ID#:_______________________
(4)
Accredited Investor. The undersigned is an accredited investor as
defined in Regulation D promulgated under the Securities Act of 1933, as
amended.
[SIGNATURE OF HOLDER]
Name of Investing Entity:
________________________________________________________________________
Signature
of Authorized Signatory of Investing Entity:
_________________________________________________
Name of Authorized
Signatory:
___________________________________________________________________
Title of
Authorized Signatory:
____________________________________________________________________
Date:
________________________________________________________________________________________
EXHIBIT B
ASSIGNMENT FORM
(To assign the foregoing Warrant, execute this form and
supply required information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to
Name: |
|
|
(Please Print) |
|
|
Address: |
|
|
(Please Print) |
Dated: _______________ __, ______
Holders Signature: ____________________________________
Holders Address:
____________________________________
Alkaline Water (NASDAQ:WTER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Alkaline Water (NASDAQ:WTER)
Historical Stock Chart
From Oct 2023 to Oct 2024